Abstract
Results with docetaxel as single drug in squamous-cell head and neck cancer have been encouraging. The purpose of the present phase II study is to evaluate the antitumour efficacy and toxicity of the combination of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck (SCCHN) for whom no curative therapy is available.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Annals of oncology : official journal of the European Society for Medical Oncology / ESMO |
| Vol/bind | 11 |
| Udgave nummer | 7 |
| Sider (fra-til) | 845-9 |
| Antal sider | 5 |
| Status | Udgivet - 1 jul. 2000 |